Objectif Conjunctivitis is a major health issue affecting more than 1100 million people worldwide. Currently, the market for bacterial & allergic conjunctivitis is mainly covered by antibiotic eye drops and ointments, which have undesired effects in the eye microbiota and contribute to increase the resistances of pathogenic strains. Other treatments such as anti-inflammatory and antihistaminic drugs have also undesired side effects and are not useful as an immediate solution.AB-BIOTICS, a company with a broad expertise in developing functional ingredients for the pharmaceutical industry, has developed an innovative solution based on the use of probiotics. Probiotics are live micro-organisms allowing a fast and stable reestablishment of a healthy eye microbiota by providing: (1) faster anti-inflammatory and anti-histaminic effects; (2) antagonism to pathogens with no resistance risks; (3) protection against future/recurrent infections; and (4) avoidance of common side effects such as intraocular pressure rising.The effects of the selected probiotic strains have been validated through functional in vitro and in vivo tests and its safety for ocular application has also been assessed in toxicity trials in animal models. The industrial scaling up of the strain has already been achieved and is now ready for galenic formulation.In order to determine the key steps to bring PROBIOTEARS to the market within the next 2 years, the objectives of the presented feasibility study are:• Assess clinical ophthalmologists & users associations interest• Determine the most suitable formula for ophthalmic use• Define IPR strategy• Perform a deeper market & competitor analysis• Find key partners to carry out Supportive Clinical Trials in phase 2• Assess Regulatory RequirementsPROBIOTEARS is a solid high-potential innovation project aligned with AB-BIOTICS’ strategy which is expected to reinforce its European & global dimension, and generate an EBITDA of 2,14M€. Champ scientifique natural sciencesbiological sciencesmicrobiologybacteriologymedical and health sciencesclinical medicineophthalmologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepathologymedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme H2020-EU.3.2.4. - Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy H2020-EU.3.2.1. - Sustainable agriculture and forestry H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.2.2. - Sustainable and competitive agri-food sector for a safe and healthy diet Thème(s) SMEInst-07-2016-2017 - Stimulating the innovation potential of SMEs for sustainable and competitive agriculture, forestry, agri-food and bio-based sectors Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur AB BIOTICS SA Contribution nette de l'UE € 50 000,00 Adresse AV TORRE BLANCA, NUM. 57, ESADE CREAPOLIS 08172 SANT CUGAT DEL VALLES Espagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Este Cataluña Barcelona Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
